Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sun denies Ranbaxy deal insider trading suggestions

This article was originally published in Scrip

Executive Summary

Sun Pharma had moved swiftly to clarify that it has not violated insider trading rules, amid suggestions that India's markets regulator may consider a preliminary probe into the significant spike in Ranbaxy's shares on local bourses ahead of its acquisition by Sun.

You may also be interested in...



Sun US Chief Gandhi Settles Insider Trading Case

Top Sun Pharma executive Abhay Gandhi and his wife have settled a case pertaining to alleged insider trading in shares of Ranbaxy around the time of  the company’s acquisition by Sun from Daiichi Sankyo in 2014. Sun, which has been firefighting a raft of governance concerns, has vouched for the executive’s integrity.

Sun US Chief Settles Insider Trading Case

Top Sun Pharma executive Abhay Gandhi and his wife have settled a case pertaining to alleged insider trading in shares of Ranbaxy around the time of  the company’s acquisition by Sun from Daiichi Sankyo in 2014. Sun, which has been firefighting a raft of governance concerns, has vouched for the executive’s integrity.

Sun Claims It Played By Rulebook As Corporate Governance Allegations Smoulder

Sun Pharma, which has been hit by allegations of grave lapses in corporate governance practices, has given its side of the story, essentially emphasizing that it has done no wrong. The company, however, signaled that it is open to reviewing certain operational arrangements should that improve investor confidence.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1122434

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel